BioPharmSignal logoBioPharmSignal

Biotech News

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

Relmada (RLMD)RelmadaEarnings

RLMD (RLMD) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is rlmd.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

RLMDRelmada2026-07-16 11:05 EST

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

RLMDRelmada2026-05-06 11:00 EST

Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

View all latest news

Relmada

Bladder Cancer Drug-Device Company Relmada Therapeutics develops NDV-01 for localized treatment of non-muscle invasive bladder cancer. NDV-01 The system delivers gemcitabine locally and continuously within the bladder, seeking durable exposure while limiting systemic toxicity. RESCUE Program The Phase 3 RESCUE program will evaluate...

Recent company news

RLMDRelmada2026-07-28 12:30 EST

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer

RLMDRelmada2026-07-16 11:05 EST

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

RLMDRelmada2026-06-29 11:00 EST

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

RLMDRelmada2026-06-11 11:00 EST

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

RLMDRelmada2026-05-28 11:00 EST

Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference

Stock data

Close
4.63 USD
Market cap
673.4M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States